nach oben

Erschienen in:

09.01.2024 | Benigne Prostatahyperplasie | Leitlinien der DGU

Minimalinvasive Therapien des benignen Prostatasyndroms

Die deutsche S2e-Leitlinie 2023 – Teil 4/4

verfasst von: PD Dr. med. Johannes Salem, Klaus F. Becher, Thomas Bschleipfer, Kurt Dreikorn, Klaus Höfner, Stephan Madersbacher, Giuseppe Magistro, Rolf Muschter, Matthias Oelke, Oliver Reich, Malte Rieken, Sandra Schönburg, Dominik Abt

Erschienen in: Die Urologie | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Das benigne Prostatasyndrom (BPS) ist die häufigste Erkrankung des unteren Harntrakts beim Mann und kann großen Einfluss auf die Lebensqualität der Betroffenen nehmen. Instrumentelle Therapien sind häufig, und viele Patienten streben mittlerweile eine operative Therapie mit weniger Morbidität als bei den klassischen Prostataoperationen an.

Ziel der Arbeit (Fragestellung)

Es handelt sich um die Darstellung und evidenzbasierte Bewertung der minimalinvasiven Therapie (MIT) des BPS.

Material und Methoden

Der Artikel liefert eine Zusammenfassung und Übersicht der Kapitel 11–13 zur MIT des BPS der aktuellen Langfassung der deutschen S2e-Leitlinie.

Ergebnisse

Bei absoluten Operationsindikationen oder nach unzufriedenstellender oder abgelehnter medikamentöser Therapie können MIT, wie UroLift® (Neotract Inc., Pleasanton, CA, USA), Rezῡm™ (Boston Scientific, Malborough, MA, USA), iTIND™ (Olympus America Inc., Westborough, MA, USA) sowie die Prostata-Arterien-Embolisation (PAE) in Betracht gezogen werden. Diese indirekt/verzögert ablativen Therapien weisen eine geringe Morbidität auf und können auch in Lokalanästhesie durchgeführt werden. MIT sind jedoch den klassischen Prostataoperationen (mit unmittelbarer Gewebeablation) hinsichtlich Effektivität und Nachhaltigkeit unterlegen.

Schlussfolgerungen

Die aktualisierte deutsche S2e-Leitlinie erfasst und bewertet die neuen MIT des BPS, welche Alternativen bei einem selektionierten Patientenklientel darstellen.

https://register.awmf.org/assets/guidelines/043-034l_S2e_Diagnostik_Therapie_benignes_Prostatasyndrom_2023-04.pdf

Dixon CM, Rijo Cedano E, Mynderse LA, Larson TR (2015) Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm(®) system: evaluation of acute ablative capabilities in the human prostate. RRU 7:13–18. https://doi.org/10.2147/rru.s74040CrossRef

Mynderse LA, Hanson D, Robb RA, Pacik D, Vit V, Varga G, Wagrell L, Tornblom M, Cedano ER, Woodrum DA, Dixon CM, Larson TR (2015) Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3‑dimensional renderings. Urology 86(1):122–127. https://doi.org/10.1016/j.urology.2015.03.021CrossRefPubMed

McVary KT, Rogers T, Roehrborn CG (2019) Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic Hyperplasia: 4‑year results from randomized controlled study. Urology 126:171–179. https://doi.org/10.1016/j.urology.2018.12.041CrossRefPubMed

Dixon CM, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, Larson TR, Mynderse LA (2016) Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. RRU 8:207–216. https://doi.org/10.2147/rru.s119596CrossRef

Johnston MJ, Noureldin M, Abdelmotagly Y, Paramore L, Gehring T, Nedas TG, Rajkumar G, Emara A, Hindley RG (2020) Rezum water vapour therapy: promising early outcomes from the first UK series. BJU Int 126(5):557–558. https://doi.org/10.1111/bju.15203CrossRefPubMed

McConnell JD, Roehrborn CG, Bautista O, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno AC, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398CrossRefPubMed

McVary KT, Rogers T, Mahon J, Gupta NK (2018) Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med 15(12):1728–1738. https://doi.org/10.1016/j.jsxm.2018.10.006CrossRefPubMed

Gupta N, Rogers T, Holland B, Helo S, Dynda D, McVary KT (2018) Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol 200(2):405–413. https://doi.org/10.1016/j.juro.2018.02.3088CrossRefPubMed

10.

Amparore D, Fiori C, Valerio M, Schulman C, Giannakis I, De Cillis S, Kadner G, Porpiglia F (2020) 3‑Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-020-00281-5CrossRefPubMed

11.

Miller LE, Te AE, Bhattacharyya SK, Lilienfeld S, Dornbier RA, McVary KT (2020) A novel metric for treatment durability in clinical trials of minimally invasive treatments for benign prostatic hyperplasia. Expert Rev Med Devices 17(4):365–369. https://doi.org/10.1080/17434440.2020.1742699CrossRefPubMed

12.

McVary KT, Holland B, Beahrs JR (2020) Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 23(2):303–308. https://doi.org/10.1038/s41391-019-0187-5CrossRefPubMed

13.

Bole R, Gopalakrishna A, Kuang R, Alamiri J, Yang DY, Helo S, Ziegelmann MJ, Köhler TS (2020) Comparative postoperative outcomes of Rezūm prostate ablation in patients with large versus small glands. J Endourol 34(7):778–781. https://doi.org/10.1089/end.2020.0177CrossRefPubMed

14.

McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, Rousseau M, Beahrs JR, Kaminetsky J, Cowan BE, Cantrill CH, Mynderse LA, Ulchaker JC, Larson TR, Dixon CM, Roehrborn CG (2016) Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 195(5):1529–1538. https://doi.org/10.1016/j.juro.2015.10.181CrossRefPubMed

15.

Garden EB, Shukla D, Ravivarapu KT, Kaplan SA, Reddy AK, Small AC, Palese MA (2021) Rezum therapy for patients with large prostates (≥ 80 g): initial clinical experience and postoperative outcomes. World J Urol. https://doi.org/10.1007/s00345-020-03548-7 (1–8)CrossRefPubMedPubMedCentral

16.

Darson MF, Alexander EE, Schiffman ZJ, Lewitton M, Light RA, Sutton MA, Delgado-Rodriguez C, Gonzalez RR (2017) Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. RRU 9:159–168. https://doi.org/10.2147/rru.s143679CrossRef

17.

Jung JH, Reddy B, McCutcheon KA, Borofsky M, Narayan V, Kim MH, Dahm P (2019) Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 5(5):Cd12832. https://doi.org/10.1002/14651858.CD012832.pub2CrossRefPubMed

18.

Rukstalis D, Grier D, Stroup SP, Tutrone R, de Souza E, Freedman S, David R, Kamientsky J, Eure G (2019) Prostatic urethral lift (PUL) for obstructive median lobes: 12 month results of the Medlift study. Prostate Cancer Prostatic Dis 22(3):411–419. https://doi.org/10.1038/s41391-018-0118-xCrossRefPubMed

19.

Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ, Roehrborn CG, Woo HH (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79(1):5–11. https://doi.org/10.1016/j.urology.2011.10.021CrossRefPubMed

20.

McNicholas TA, Woo HH, Chin PT, Bolton D, Fernández Arjona M, Sievert KD, Schoenthaler M, Wetterauer U, Vrijhof EJ, Gange S, Montorsi F (2013) Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 64(2):292–299. https://doi.org/10.1016/j.eururo.2013.01.008CrossRefPubMed

21.

Perera M, Roberts MJ, Doi SA, Bolton D (2015) Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 67(4):704–713. https://doi.org/10.1016/j.eururo.2014.10.031CrossRefPubMed

22.

Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Brown BT, McVary KT, Te AE, Gholami SS, Rashid P, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rukstalis DB (2013) The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol 190(6):2161–2167. https://doi.org/10.1016/j.juro.2013.05.116CrossRefPubMed

23.

Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P, Thavaseelan J, McVary KT (2012) Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9(2):568–575. https://doi.org/10.1111/j.1743-6109.2011.02568.xCrossRefPubMed

24.

Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC, Roehrborn CG (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108(1):82–88. https://doi.org/10.1111/j.1464-410X.2011.10342.xCrossRefPubMed

25.

Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rashid P (2015) Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 22(3):7772–7782PubMed

26.

Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Herron S, Rashid P, Rukstalis DB (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 24(3):8802–8813PubMed

27.

Miller LE, Chughtai B, Dornbier RA, McVary KT (2020) Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2,000 patients. J Urol 204(5):1019–1026. https://doi.org/10.1097/JU.0000000000001132CrossRefPubMed

28.

Sønksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Montorsi F, Patterson JM, Fahrenkrug L, Schoenthaler M, Gratzke C (2015) Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 68(4):643–652. https://doi.org/10.1016/j.eururo.2015.04.024CrossRefPubMed

29.

Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Patterson JM, Fahrenkrug L, Schoenthaler M, Sonksen J (2017) Prostatic urethral lift vs transurethral resection of the prostate: 2‑year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119(5):767–775. https://doi.org/10.1111/bju.13714CrossRefPubMed

30.

Roehrborn CG, Rukstalis DB (2021) Prostatic urethral lift versus medical therapy: examining the impact on sexual function in men with benign prostatic hyperplasia. Eur Urol Focus. https://doi.org/10.1016/j.euf.2020.12.013CrossRefPubMed

31.

Chughtai B, Elterman D, Shore N, Gittleman M, Motola J, Pike S, Hermann C, Terrens W, Kohan A, Gonzalez RR, Katz A, Schiff J, Goldfischer E, Grunberger I, Tu LM, Alshak MN, Kaminetzky J (2020) The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a multicenter, randomized, controlled trial. Urology. https://doi.org/10.1016/j.urology.2020.12.022CrossRefPubMed

32.

De Nunzio C, Cantiello F, Fiori C, Crocerossa F, Tognoni P, Amparore D, Baldassarri V, Elbers JR, Sancha FG, Porpiglia F (2020) Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6‑month interim results of the MT-06-study. World J Urol. https://doi.org/10.1007/s00345-020-03418-2CrossRefPubMedPubMedCentral

33.

Martins Pisco J, Pereira J, Rio Tinto H, Fernandes L, Bilhim T (2012) How to perform prostatic arterial embolization. Tech Vasc Interv Radiol 15(4):286–289. https://doi.org/10.1053/j.tvir.2012.09.002CrossRefPubMed

34.

Mordasini L, Hechelhammer L, Diener PA, Diebold J, Mattei A, Engeler D, Mullhaupt G, Kim SK, Schmid HP, Abt D (2018) Prostatic artery embolization in the treatment of localized prostate cancer: a bicentric prospective proof-of-concept study of 12 patients. J Vasc Interv Radiol 29(5):589–597. https://doi.org/10.1016/j.jvir.2018.01.766CrossRefPubMed

35.

McWilliams JP, Bilhim TA, Carnevale FC, Bhatia S, Isaacson AJ, Bagla S, Sapoval MR, Golzarian J, Salem R, McClure TD, Kava BR, Spies JB, Sabharwal T, McCafferty I, Tam AL (2019) Society of interventional radiology multisociety consensus position statement on prostatic artery embolization for treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia: from the society of interventional radiology, the cardiovascular and interventional radiological society of Europe, societe Francaise de radiologie, and the British society of interventional radiology: endorsed by the Asia pacific society of cardiovascular and interventional radiology, Canadian association for interventional radiology, Chinese college of interventionalists, interventional radiology society of Australasia, Japanese society of interventional radiology, and Korean society of interventional radiology. J Vasc Interv Radiol 30(5):627–637 e621. https://doi.org/10.1016/j.jvir.2019.02.013CrossRefPubMed

36.

Abt D, Mullhaupt G, Mordasini L, Gusewell S, Markart S, Zumstein V, Kessler TM, Schmid HP, Engeler DS, Hechelhammer L (2019) Outcome prediction of prostatic artery embolization: post hoc analysis of a randomized, open-label, non-inferiority trial. BJU Int 124(1):134–144. https://doi.org/10.1111/bju.14632CrossRefPubMed

37.

Jung JHMK, Borofsky M, Young S, Golzarian J, Reddy B, Shin TY, Kim MH, Narayan V, Dahm P (2020) Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst RevCD012867. https://doi.org/10.1002/14651858.CD012867.pub2 (2020, Issue 12)CrossRefPubMedPubMedCentral

38.

Zumstein V, Betschart P, Vetterlein MW, Kluth LA, Hechelhammer L, Mordasini L, Engeler DS, Kessler TM, Schmid HP, Abt D (2019) Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus 5(6):1091–1100. https://doi.org/10.1016/j.euf.2018.09.005CrossRefPubMed

39.

Abt D, Hechelhammer L, Mullhaupt G, Markart S, Gusewell S, Kessler TM, Schmid HP, Engeler DS, Mordasini L (2018) Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 361:k2338. https://doi.org/10.1136/bmj.k2338CrossRefPubMedPubMedCentral

40.

Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M (2016) Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) Due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol 39(1):44–52. https://doi.org/10.1007/s00270-015-1202-4CrossRefPubMed

41.

Gao YA, Huang Y, Zhang R, Yang YD, Zhang Q, Hou M, Wang Y (2014) Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate—a prospective, randomized, and controlled clinical trial. Radiology 270(3):920–928. https://doi.org/10.1148/radiol.13122803CrossRefPubMed

42.

Insausti I, Saez de Ocariz A, Galbete A, Capdevila F, Solchaga S, Giral P, Bilhim T, Isaacson A, Urtasun F, Napal S (2020) Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 31(6):882–890. https://doi.org/10.1016/j.jvir.2019.12.810CrossRefPubMed

43.

Radwan A, Farouk A, Higazy A, Samir YR, Tawfeek AM, Gamal MA (2020) Prostatic artery embolization versus transurethral resection of the prostate in management of benign prostatic hyperplasia. Prostate Int 8(3):130–133. https://doi.org/10.1016/j.prnil.2020.04.001CrossRefPubMedPubMedCentral

44.

Zhu L, Huang C (2018) Prostate artery embolization and transurethral resection of prostate for benign prostatic hyperplasia: a prospective randomized ontrolled trial. Chin J Interv Imaging Ther 15(3):134–138

45.

Pisco JM, Bilhim T, Costa NV, Torres D, Pisco J, Pinheiro LC, Oliveira AG (2019) Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia. Eur Urol. https://doi.org/10.1016/j.eururo.2019.11.010CrossRefPubMed

46.

Pisco JM, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, Duarte M, Oliveira AG (2016) Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol 27(8):1115–1122. https://doi.org/10.1016/j.jvir.2016.04.001CrossRefPubMed

47.

Knight GM, Talwar A, Salem R, Mouli S (2021) Systematic review and meta-analysis comparing prostatic artery embolization to gold-standard transurethral resection of the prostate for benign prostatic hyperplasia. Cardiovasc Intervent Radiol 44(2):183–193. https://doi.org/10.1007/s00270-020-02657-5CrossRefPubMed

48.

Jiang YL, Qian LJ (2019) Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. BMC Urol 19(1):11. https://doi.org/10.1186/s12894-019-0440-1CrossRefPubMedPubMedCentral

49.

Xu XJ, Li J, Huang XZ, Liu Q (2020) An updated meta-analysis of prostatic arterial embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. World J Urol 38(10):2455–2468. https://doi.org/10.1007/s00345-019-03044-7CrossRefPubMed

50.

Feng S, Tian Y, Liu W, Li Z, Deng T, Li H, Wang K (2017) Prostatic arterial embolization treating moderate-to-severe lower urinary tract symptoms related to benign prostate hyperplasia: a meta-analysis. Cardiovasc Intervent Radiol 40(1):22–32. https://doi.org/10.1007/s00270-016-1516-xCrossRefPubMed

51.

Shim SR, Kanhai KJ, Ko YM, Kim JH (2017) Efficacy and safety of prostatic arterial embolization: systematic review with meta-analysis and meta-regression. J Urol 197(2):465–479. https://doi.org/10.1016/j.juro.2016.08.100CrossRefPubMed

52.

Abt D, Mullhaupt G, Hechelhammer L, Markart S, Gusewell S, Schmid HP, Mordasini L, Engeler DS (2021) Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2‑yr outcomes of a randomised, open-label, single-centre trial. Eur Urol 80(1):34–42. https://doi.org/10.1016/j.eururo.2021.02.008CrossRefPubMed

53.

Ray AF, Powell J, Speakman MJ, Longford NT, DasGupta R, Bryant T, Modi S, Dyer J, Harris M, Carolan-Rees G, Hacking N (2018) Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int 122(2):270–282. https://doi.org/10.1111/bju.14249CrossRefPubMed

54.

ntunes AA, Carnevale FC, da Motta Filho Yoshinaga LJMEM (2013) Clinical, laboratorial, and urodynamic findings of prostatic artery embolization for the treatment of urinary retention related to benign prostatic hyperplasia. A prospective single-center pilot study. Cardiovasc Intervent Radiol 36(4):978–986. https://doi.org/10.1007/s00270-013-0611-5CrossRef

55.

https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts. Zugegriffen: 1. Sept. 2023

56.

- https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline. Zugegriffen: 01.09.

57.

Speakman MJ, Cornu JN, Gacci M, Gratzke C, Mamoulakis C, Herrmann TRW, Omar MI, Rieken M, Tikkinen KAO, Gravas S (2019) What is the required certainty of evidence for the implementation of novel techniques for the treatment of benign prostatic obstruction? Eur Urol Focus 5(3):351–356. https://doi.org/10.1016/j.euf.2019.05.014CrossRefPubMed

Titel: Minimalinvasive Therapien des benignen Prostatasyndroms
Die deutsche S2e-Leitlinie 2023 – Teil 4/4
verfasst von: PD Dr. med. Johannes Salem
Klaus F. Becher
Thomas Bschleipfer
Kurt Dreikorn
Klaus Höfner
Stephan Madersbacher
Giuseppe Magistro
Rolf Muschter
Matthias Oelke
Oliver Reich
Malte Rieken
Sandra Schönburg
Dominik Abt
Publikationsdatum: 09.01.2024
Verlag: Springer Medizin
Schlagwörter: Benigne Prostatahyperplasie
Benigne Prostatahyperplasie
TURP
Erschienen in: Die Urologie / Ausgabe 1/2024
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-023-02249-4

Passend zum Thema

Phytotherapie bei CPPS

Pollstimol®: Leitliniengerechte Prostatitis-Therapie

In 90 % der Prostatitis-Fälle handelt es sich um eine chronische abakterielle Prostatitis (chronic pelvic pain syndrome, CPPS) mit anhaltender Entzündungsreaktion und Schwellung der Prostata. Als leitliniengerechte Behandlungsoption mit guter Evidenz hat sich das Phytotherapeutikum Pollstimol® etabliert.

Springer Medizin

Zusammenfassung

Hintergrund

Ziel der Arbeit (Fragestellung)

Material und Methoden

Ergebnisse

Schlussfolgerungen

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Termine

Patientenveranstaltungen in der deutschen Urologie: Trend zu Hybridformaten?

Gesamtüberleben und krebsspezifische Mortalität bei Patienten mit „very high-risk“ nicht-muskelinvasivem Urothelkarzinom der Harnblase (NMIBC)

Prolapsassoziierte Symptome – Heilung als Ziel der Beckenbodenchirurgie

Mitteilungen der DGU

Erratum zu: Chancen der PSMA(prostataspezifisches Membranantigen)-Hybridbildgebung beim Prostatakarzinom

Passend zum Thema

Pollstimol®: Leitliniengerechte Prostatitis-Therapie